Patents Examined by Deborah Crouch
  • Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
    Patent number: 8278104
    Abstract: The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: October 2, 2012
    Assignee: Kyoto University
    Inventors: Shinya Yamanaka, Kazutoshi Takahashi, Keisuke Okita
  • Nonalcoholic steatohepatitis model rodent and fatty liver model rodent
    Patent number: 8278499
    Abstract: Disclosed is a nonhuman animal showing the symptoms of human nonalcoholic steatohepatitis which is obtained by transplanting human hepatocytes into an immunodeficient hepatopathic nonhuman animal to produce a chimeric nonhuman animal and then transplanting human hepatocytes that are propagated in the body of the chimeric nonhuman animal into an immunodeficient hepatopathic nonhuman animal of the same species as the immunodeficient hepatopathic nonhuman animal described above, as well as a nonhuman animal showing the symptoms of human fatty liver which is obtained by transplanting human hepatocytes into an immunodeficient hepatopathic nonhuman animal to produce a chimeric nonhuman animal.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: October 2, 2012
    Assignees: Hiroshima Industrial Promotion Organization, Phoenixbio Co., Ltd., Hiroshima University
    Inventors: Chise Mukaidani, Katsutoshi Yoshizato, Miho Kataoka
  • Methods and compositions for treating motor neuron diseases comprising mesenchymal stem cells
    Patent number: 8277795
    Abstract: Disclosed herein are a composition for treating motor neuron diseases, particularly amyotrophic lateral sclerosis (ALS), using mesenchymal stem cells, and a method for treating motor neuron diseases using the composition. The composition and treatment method can provide effective therapy for motor neuron diseases, particularly for amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: October 2, 2012
    Assignee: Corestem Co., Ltd.
    Inventors: Hee Tae Kim, Kyung Suk Kim, Seung Hyun Kim, Young Gyu Chai, Seong Ho Koh, Hyun Young Kim, Mi Ran Choi, Ji-Yoon Park, Kyoung Hwa Jung
  • Preparation of human embryonic stem cells
    Patent number: 8273569
    Abstract: A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (?); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: September 25, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: James A. Thomson
  • OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells
    Patent number: 8268620
    Abstract: Methods for reprogramming primate somatic cells to pluripotency using an episomal vector that does not encode an infectious virus are disclosed. Pluripotent cells produced in the methods are also disclosed.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: September 18, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James Thomson, Junying Yu
  • Extracellular matrix compositions produced under hypoxic culture conditions
    Patent number: 8257947
    Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: September 4, 2012
    Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
  • Methods and platforms for drug discovery using induced pluripotent stem cells
    Patent number: 8257941
    Abstract: The present invention involves methods for identifying an agent that corrects a phenotype associated with a health condition or a predisposition for a health condition. The invention also involves methods for identifying a diagnostic cellular phenotype, determining the risk of a health condition in a subject, methods for reducing the risk of drug toxicity in a human subject, and methods for identifying a candidate gene that contributes to a human disease. The invention also discloses human induced pluripotent stem cell lines.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: September 4, 2012
    Assignee: Kyoto University
    Inventors: Kazuhiro Sakurada, Kenneth J. Seidenman
  • Preparation of adult stem cell-derived connective tissue progenitors
    Patent number: 8241902
    Abstract: Methods of generating and expanding proliferative, multipotent connective tissue progenitor cells from adult stem cells are provided. Also provided are methods of generating functional tendon grafts in vitro and bone, cartilage and connective tissues in vivo using the isolated cell preparation of connective tissue progenitor cells.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: August 14, 2012
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Joseph Itskovitz-Eldor, Shahar Cohen
  • Hypertonic conditions for cell and oocyte enucleation
    Patent number: 8222480
    Abstract: Compositions and methods are provided for the efficient and reproducible generation of clone animals of all developmental stages. Also provided are methods of use of the same in reproductive and therapeutic cloning protocols.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: July 17, 2012
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Michele Boiani, Kenneth John McLaughlin, Hans R. Schöler, Sigrid Eckardt
  • Tissue culture medium comprising transforming growth factor beta 1 and basic fibroblast growth factor
    Patent number: 8222034
    Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: July 17, 2012
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Induced pluripotent stem cells produced using reprogramming factors and a rho kinase inhibitor or a histone deacetylase inhibitor
    Patent number: 8211697
    Abstract: Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: July 3, 2012
    Assignee: Kyoto University
    Inventors: Kazuhiro Sakurada, Hideki Masaki, Tetsuya Ishikawa, Shunichi Takahashi
  • Methods of derivation of neuronal progenitor cells from embryonic stem cells
    Patent number: 8211698
    Abstract: The invention provides neuronal progenitor cells, populations and cultures of cells, cell compositions and methods of producing neuronal progenitor cells. Neuronal progenitor cells can be prepared from embryonic stem cells, such as human embryonic stem cells.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: July 3, 2012
    Assignee: California Stem Cells, Inc.
    Inventor: Aleksandra Jovanovic Poole
  • CYP46A1 gene for the treatment of alzheimer's disease
    Patent number: 8198257
    Abstract: The invention relates to a viral vector for treating Alzheimers disease, which vector comprises a cholesterol 24-hydroxylase (CYP46A1) encoding nucleic acid. In a preferred embodiment, the viral vector may be an Adeno-Associated-Virus (AAV) vector, preferably an AVV5 vector. The vector may be useful for the manufacture of a pharmaceutical composition for the treatment of Alzheimers disease in a subject, wherein the vector is to be administered directly into the brain of the subject or by intravenous or intrathecal injection.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: June 12, 2012
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Patrick Aubourg, Nathalie Cartier-Lacave, Eloise Hudry
  • Human dental follicle stem cells and methods for obtaining
    Patent number: 8192987
    Abstract: A stem cell which is obtainable from the non-embryonic tissue isolated from the dental follicle of tooth or wisdom tooth which are able to differentiate into a periodontal ligament like membrane structure.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: June 5, 2012
    Assignee: TissueDent GmbH & Co. KG
    Inventors: Jörg Schierholz, Hans-Florian Zeilhofer, Karl-Heinz Hoffmann, Christian Morsczexk, Norbert Brenner
  • Composition comprising recombinant nucleic acid encoding Sox2, Oct-4, Nanog and Lin28
    Patent number: 8183038
    Abstract: The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: May 22, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Junying Yu
  • Transgenic pig model for a hereditary neurodegenerative autosomal dominant disease
    Patent number: 8173861
    Abstract: The present invention discloses a non-human animal model for a hereditary autosomal dominant disease. The non-human animal model expresses at least one phenotype associated with the disease and is obtained by a genetic determinant. The invention also relates to sperm cells and embryos comprising the genetic determinant for an autosomal dominant disease. Furthermore, methods for producing the non-human animal model, sperm cell, and embryos are disclosed.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: May 8, 2012
    Assignee: Aarhus Universitet
    Inventors: Lone Bruhn Madsen, Christian Bendixen, Knud Larsen, Connie Jakobsen Juhl, Bo Thomsen
  • Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion
    Patent number: 8173860
    Abstract: The invention provides, in part, methods for the production of proteins in a transgenic non-human mammal, wherein the proteins are transported from the blood to the mammary gland for secretion in milk. The transport of the protein to the mammary gland and/or milk is facilitated by binding to a transport receptor in the mammary gland.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: May 8, 2012
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Harry M. Meade, Daniel Pollock
  • Muller cells de-differentiated to cells expressing markers of neural cell progenitors
    Patent number: 8173426
    Abstract: A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult Müller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the Müller cells into a progenitor phenotype.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: May 8, 2012
    Assignee: The Institute of Ophthalmology
    Inventors: Gloria Astrid Limb, Peng Tee Khaw
  • Method of making a hair
    Patent number: 8158423
    Abstract: A method of making a hair, including a step of culturing an undifferentiated cell of a mammal to produce an embryoid body and a step of further culturing the embryoid body is provided, wherein the culturing step is to culture the embryoid body on a three-dimensional matrix for 5 to 12 days. Furthermore, a biological material obtainable by the method of making a hair as described above is provided. Moreover, a biological material for a screening system of evaluating a medical product or the like, obtainable by utilizing the method of making a hair as described above is provided.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: April 17, 2012
    Assignee: Matsumoto Dental University
    Inventors: Hidehiro Ozawa, Mariko Yamaki, Makoto Asashima, Satoshi Ebina
  • C1 inhibitor with short half-life transient treatment
    Patent number: RE43691
    Abstract: The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: September 25, 2012
    Assignee: Pharming Intellectual Property B.V.
    Inventor: Johannes Henricus Nuijens